Penumbra Stock Surges 142% in Volume, Ranks 435th as STORM-PE Trial Enrollment Completes

On June 16, 2025, Penumbra (PEN) saw a significant increase in trading volume, reaching 2.29 billion, a 142.47% rise from the previous day. This surge placed Penumbra at the 435th position in the day's stock market rankings. The stock price of Penumbra rose by 1.74%, marking its third consecutive day of gains, with a total increase of 3.02% over the past three days.

Penumbra, Inc. has announced the completion of enrollment for its landmark STORM-PE randomized controlled trial. This trial is the first of its kind, comparing computer-assisted technology with standard anticoagulation treatment. The STORM-PE trial enrolled 100 patients to evaluate the effectiveness of Penumbra's Lightning Flash technology.

This milestone in the STORM-PE trial is expected to have a positive impact on Penumbra's stock price, as it demonstrates the company's commitment to innovation and its potential to revolutionize the treatment of pulmonary embolism. The successful completion of enrollment in this pivotal trial is a significant step forward for Penumbra, and investors are likely to view this development favorably.